Open Label Safety Study in Acute Treatment of Migraine
NCT03266588 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 3019
Last updated 2023-02-16
Summary
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
Conditions
- Migraine, With or Without Aura
Interventions
- DRUG
-
Rimegepant
75 mg oral tablet
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-30
- Primary Completion
- 2019-07-15
- Completion
- 2019-07-15
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT05207865 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123 ·Status: COMPLETED ·Phase: PHASE4
-
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
NCT06412965 ·Status: COMPLETED
-
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
NCT05371652 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
NCT04574362 ·Status: COMPLETED ·Phase: PHASE3
-
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
NCT06467370 ·Status: COMPLETED
-
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
NCT05217927 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 ·Status: RECRUITING ·Phase: PHASE3
-
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
NCT01430442 ·Status: COMPLETED ·Phase: PHASE2
-
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832 ·Status: RECRUITING
-
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
NCT04408794 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
NCT05810038 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
NCT06532357 ·Status: COMPLETED
-
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·Status: RECRUITING ·Phase: PHASE3
-
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
NCT05709106 ·Status: COMPLETED
-
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
NCT05198245 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
NCT02174861 ·Status: COMPLETED ·Phase: PHASE2
-
Consistency of Response With Rimegepant in Acute Treatment of Migraine
NCT06898047 ·Status: ACTIVE_NOT_RECRUITING
-
Cluster Headache Treatment With Rimegepant
NCT05264714 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
NCT03308968 ·Status: COMPLETED ·Phase: PHASE3